|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/12 Hi Tech Pharmacal Co Inc 10-Q 1/31/12 35:1.7M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 366K
2: EX-31.1 Section 302 CEO Certification HTML 19K
3: EX-31.2 Section 302 CFO Certification HTML 19K
4: EX-32 Section 906 CEO and CFO Certification HTML 12K
19: R1 Document And Entity Information HTML 32K
13: R2 Condensed Consolidated Balance Sheets HTML 129K
17: R3 Condensed Consolidated Balance Sheets HTML 33K
(Parenthetical)
21: R4 Condensed Consolidated Statements Of Operations HTML 118K
32: R5 Condensed Consolidated Statements Of Cash Flows HTML 91K
14: R6 Basis Of Presentation HTML 23K
16: R7 Business HTML 22K
12: R8 Revenue Recognition HTML 15K
10: R9 Net Income Per Share HTML 18K
33: R10 Inventory HTML 22K
23: R11 Property And Equipment HTML 28K
22: R12 Intangible Assets HTML 44K
27: R13 Long-Term Debt HTML 19K
28: R14 Freight Expense HTML 14K
26: R15 Stock-Based Compensation HTML 34K
29: R16 Product Divestitures HTML 21K
18: R17 Income Taxes HTML 21K
20: R18 Contingencies And Other Matters HTML 41K
25: R19 Recent Accounting Pronouncements HTML 24K
35: R20 Comprehensive Income HTML 26K
31: R21 Significant Customers And Concentration Of Credit HTML 19K
Risk
15: R22 Fair Value Measurements HTML 29K
24: R23 Subsequent Events HTML 15K
34: XML IDEA XML File -- Filing Summary XML 47K
11: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 180K
7: EX-101.CAL XBRL Calculations -- hitk-20120131_cal XML 90K
5: EX-101.INS XBRL Instance -- hitk-20120131 XML 251K
8: EX-101.LAB XBRL Labels -- hitk-20120131_lab XML 341K
9: EX-101.PRE XBRL Presentations -- hitk-20120131_pre XML 187K
6: EX-101.SCH XBRL Schema -- hitk-20120131 XSD 50K
30: ZIP XBRL Zipped Folder -- 0001193125-12-106351-xbrl Zip 40K
| Section 302 CFO Certification |
Exhibit 31.2
HI-TECH PHARMACAL CO., INC.
CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, WILLIAM PETERS, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Hi-Tech Pharmacal Co., Inc. |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: March 9, 2012
| By: | /s/ William Peters | |
| William Peters | ||
| Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/9/12 | None on these Dates | ||
| For Period end: | 1/31/12 | |||
| List all Filings | ||||